[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350697-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350697-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pancreatic-cancer-early-detection-biomarkers-for-high-risk-individuals-insights-from-the-precede-consortium","Pancreatic Cancer Early Detection Biomarkers for High-Risk Individuals: Insights From the PRECEDE Consortium","","Pancreatic ductal adenocarcinoma (PDAC) is highly lethal due to asymptomatic progression, late-stage diagnosis, and limited treatment effectiveness. Early detection strategies focus on imaging features and liquid biopsy biomarkers able to identify PDAC and high-grade precursors before symptoms emerge in high-risk individuals. Guideline-aligned, classical imaging surveillance supports screening, while organ-specific fluid analyses such as cyst fluid and pancreatic juice provide complementary approaches with improved specificity. Advances in radiomics, liquid biopsy, microbiome, and multi-omics profiling extend current detection frontiers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pancreatic-cancer-early-detection-biomarkers-for-high-risk-individuals-insights-from-the-precede-consortium/350697/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pancreatic-cancer-early-detection-biomarkers-for-high-risk-individuals-insights-from-the-precede-consortium/350697.png","ImageObject",300,407,{"name":42,"@type":43},"RuangKosong","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is early detection of pancreatic cancer challenging in high-risk individuals?","Question",{"text":63,"@type":64},"PDAC often progresses without symptoms, leading to late-stage diagnosis. Precursor lesions can be difficult to diagnose non-invasively and may be invisible or hard to grade before resection.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What roles do imaging strategies play in screening high-risk individuals?",{"text":68,"@type":64},"Classical imaging-based surveillance aligned with current guidelines underpins screening by enabling monitoring for features related to PDAC and its precursors.",{"name":70,"@type":61,"acceptedAnswer":71},"How do liquid biopsy biomarkers complement imaging-based surveillance?",{"text":72,"@type":64},"Organ-specific fluid analyses such as cyst fluid and pancreatic juice can add complementary information and improve specificity for detecting PDAC and high-grade precursors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350697,1790886976,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090883219,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","International Journal of Cancer  \nREVIEW  OPEN ACCESS   \nPancreatic Cancer Early Detection Biomarkers for High-Risk Individuals: Insights From the  \nPRECEDE Consortium  \nChristine Worthington1 | Maria Raitses-Gurevich2 | Giulio Innamorati3 | Phil A. Hart4 | Thomas M. Wilkie5 | Noam Tau6 | Dana Brin6 | Doron Yablecovitch7 | Ido Laish7 | Dove Keith8 | Kurt Giles9 | Jennifer B. Permuth10  | Diane M. Simeone11 | George Zogopoulos12 | Randall E. Brand13 | John J. Graff14 | Julie Earl15  | On behalf of the PRECEDE Consortium  \n1Division of Gastroenterology, Hepatology, and Nutrition, College of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA | 2The Jusidman Cancer Center, Chaim Sheba Medical Center, Tel HaShomer Hospital, Ramat Gan, Israel | 3Laboratory of Translational Surgery, Department of Surgery, Dentistry, Maternity and Infant, University of Verona, Verona, Italy | 4Division of Gastroenterology, Hepatology, and Nutrition, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA | 5Pharmacology Department, UT Southwestern Medical Center, Dallas, Texas, USA | 6Department of Diagnostic Imaging, Chaim Sheba Medical Center, Tel HaShomer Hospital, Tel Aviv University, Ramat Gan,  \nIsrael | 7Gastroenterology Institute, Chaim Sheba Medical Center, Tel HaShomer Hospital, Tel Aviv University, Ramat Gan, Israel | 8Brenden-Colson Center for Pancreatic Care, Oregon Health and Science University, Portland, Oregon, USA | 9Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA | 10Department of Gastrointestinal Oncology, Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida, USA | 11Department of Surgery, University of California San Diego Health, Moores Cancer Center, San Diego, California, USA | 12Department of Surgery, Department of Oncology, McGill University and the Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada | 13Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA | 14PRECEDE Data Coordinating Center, Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA | 15Biomarkers and Personalized Approach to Cancer (BIOPAC) Group, Ramon y Cajal Health Research Institute,(IRYCIS), Madrid, Spain  \nCorrespondence: Julie Earl ([julie.earl@salud.madrid.org](julie.earl@salud.madrid.org))  \nReceived: 27 February 2026 | Revised: 27 May 2026 | Accepted: 2 June 2026  \nKeywords: biomarkers | early detection | imaging | liquid biopsy | pancreatic cancer | screening  \nABSTRACT  \nPancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers due to its asymptomatic progression, late-stage diagnosis, and treatment resistance. Efforts in early detection have centered on identifying imaging features and liquid biopsy biomarkers capable of detecting PDAC and its high-grade precursors before clinical symptoms arise in patients at elevated risk of PDAC development. Classical imaging-based surveillance strategies, aligned with current guidelines, form the foundation of screening high-risk individuals, while organ-specific fluid analyses—such as cyst fluid and pancreatic juice—offer promising complementary tools with enhanced specificity. Recent advances in radiomics, liquid biopsy, microbiome, and multi-omics profiling are expanding the frontier  \n\n| Abbreviations: 5hmC, 5-hydroxymethylcytosine; AI, artificial intelligence; ATM, ataxia-telangiectasia mutated (germline mutation); AUC, area under the curve; AUROC, area under the receiver operating characteristic; BRCA1/2, breast cancer gene 1/2; CA 19-9, carbohydrate antigen 19-9; CAPS, International Cancer of the Pancreas Screening; CDKN2A, cyclin-dependent kinase inhibitor 2A; CEA, carcinoembryonic antigen; cfDNA, cell-free DNA; circRNAs, circular RNAs; CT, computed tomography; ctDNA, circulating tumor DNA; ECM, extracellular matrix; EDRN, early de","cbCail7BYUhNeVEe","https://ap.wps.com/l/cbCail7BYUhNeVEe","pdf",691158,"English","# Abstract\n## Imaging-based surveillance and guideline alignment\n## Liquid biopsy and organ-specific fluid biomarkers\n## Emerging approaches: radiomics, microbiome, and multi-omics","[{\"question\":\"Why is early detection of pancreatic cancer challenging in high-risk individuals?\",\"answer\":\"PDAC often progresses without symptoms, leading to late-stage diagnosis. Precursor lesions can be difficult to diagnose non-invasively and may be invisible or hard to grade before resection.\"},{\"question\":\"What roles do imaging strategies play in screening high-risk individuals?\",\"answer\":\"Classical imaging-based surveillance aligned with current guidelines underpins screening by enabling monitoring for features related to PDAC and its precursors.\"},{\"question\":\"How do liquid biopsy biomarkers complement imaging-based surveillance?\",\"answer\":\"Organ-specific fluid analyses such as cyst fluid and pancreatic juice can add complementary information and improve specificity for detecting PDAC and high-grade precursors.\"}]","Pancreatic Cancer Early Detection Biomarkers for High-Risk Individuals: Insights From the PRECEDE Consortium | PDF",1790090651,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c834b8410149281a17d34db9f5469d0.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c023d711bba89ddd74c463d6438b422.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8cbe0ed56812fad197c08ce48eadb3d4.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce919d4781dc5501fd1d1b529d4121dd.webp",980,1287]